Last edition
News about "Boehringer Ingelheim"
Boehringer Ingelheim Unveils VETMEDIN Solution
VETMEDIN Solution, now available in the US, provides the same dual mode of action as VETMEDIN® Chewable Tablets.
Boehringer Ingelheim | 25/11/2024 | By Aishwarya
PhoreMost Join Hands with Boehringer Ingelheim
PhoreMost Ltd. has made a multi-project target discovery collaboration with Boehringer Ingelheim.
Boehringer Ingelheim | 04/06/2024 | By Aishwarya | 140
Boehringer Ingelheim Teams Up with Quallent to Expand Access to adalimumab-adbm Injection
Boehringer Ingelheim has signed a deal with Quallent Pharmaceuticals to help expand patient access to citrate-free adalimumab-adbm, Boehringer's biosimilar to Humira (adalimumab), in the US.
Boehringer Ingelheim | 14/05/2024 | By Aishwarya | 217
Boehringer Ingelheim Inks Second Pact with 3T Biosciences to Develop Cancer Immunotherapies
This second research partnership with 3T builds on the successful completion of the initial research partnership announced last year by the two companies.
Boehringer Ingelheim | 05/01/2024 | By Manvi | 211
Boehringer Ingelheim breaks ground on 285M API plant in Germany
Boehringer Ingelheim kicked off construction on a new 285 million euro ($315 million) plant at its German headquarters that will produce active pharmaceutical ingredients and drugs for clinical trials.
Boehringer Ingelheim | 15/06/2023 | By Sudeep Soparkar | 348
Boehringer Ingelheim starts 285M API plant construction in Germany
The Chemical Innovation Plant is expected to begin operating in 2026 at Boehringer’s base in Ingelheim, Germany
<br />
Boehringer Ingelheim | 08/05/2023 | By Sudeep Soparkar | 481
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy